+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Programmed Cell Death Protein"

From
From
From
From
From
From
From
CTLA-4 inhibitors- Competitive landscape, 2023 - Product Thumbnail Image

CTLA-4 inhibitors- Competitive landscape, 2023

  • Report
  • May 2023
  • 220 Pages
  • Global
From
Bispecific antibody - Competitive landscape, 2023 - Product Thumbnail Image

Bispecific antibody - Competitive landscape, 2023

  • Report
  • May 2023
  • 450 Pages
  • Global
From
Checkpoint Inhibitors - Competitive landscape, 2023 - Product Thumbnail Image

Checkpoint Inhibitors - Competitive landscape, 2023

  • Report
  • April 2023
  • 350 Pages
  • Global
From
Lenvatinib + pembrolizumab Emerging Drug Insight and Market Forecast - 2032 - Product Thumbnail Image

Lenvatinib + pembrolizumab Emerging Drug Insight and Market Forecast - 2032

  • Drug Pipelines
  • December 2022
  • 30 Pages
  • Global
From
From
From
From
ATEZOLIZUMAB - Emerging Insight and Market Forecast - 2030 - Product Thumbnail Image

ATEZOLIZUMAB - Emerging Insight and Market Forecast - 2030

  • Report
  • February 2021
  • 50 Pages
  • Global
From
From
From
Immuno-oncology Market - Product Thumbnail Image

Immuno-oncology Market

  • Report
  • January 2024
  • 200 Pages
  • Global
From
Loading Indicator

Programmed Cell Death Protein (PDP) is a type of protein that plays a role in the regulation of cell death in the body. It is a key component of the body's natural defense against cancer, as it helps to prevent the growth and spread of cancerous cells. In oncology drugs, PDP is used to target and destroy cancer cells, while leaving healthy cells unharmed. PDP is also used to reduce the side effects of chemotherapy and radiation therapy, as well as to reduce the risk of recurrence of cancer. PDP is also used to reduce the risk of metastasis, or the spread of cancer to other parts of the body. PDP is a rapidly growing market, with many companies developing and marketing PDP-based drugs. Some of these companies include Merck, Bristol-Myers Squibb, AstraZeneca, Novartis, and Pfizer. Show Less Read more